Breaking News, Collaborations & Alliances

AtomVie, Radiopharm Ventures Partner to Develop & Manufacture Monoclonal Antibody

177Lu-BetaBart targets the 4Ig subtype of B7-H3, the most common subtype expressed in human tumors.

Author Image

By: Charlie Sternberg

Associate Editor

AtomVie Global Radiopharma, a radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), has partnered with Radiopharm Ventures (RV) to develop and manufacture 177Lu-BetaBart, a 177Lutetium-conjugated B7-H3 targeting radioantibody.   This partnership leverages both companies’ expertise to advance novel radiotherapeutic solutions in areas of high unmet medical needs. Targeting B7-H3 B7-H3 is an immune checkpoint molecule that is overexpressed in several tumor typ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters